Joint Soreness Changes With Activity, Rest, and Time

The time the ache starts tells you what to change

Notice whether your joint hurts during movement or later that day. Also note whether rest calms it or the ache lasts through the night.

Walking, stairs, kneeling, golf, and work put different amounts of strain on a joint. One task may cause trouble while another doesn't.

Change the hardest task for a while and see whether soreness settles. Don't stop all movement unless a health provider has told you to.

When soreness keeps limiting you, QC Kinetix can examine the area and discuss non-surgical care. Natural pain treatments here mean office shots made after staff take and prepare blood.

The hope is milder pain and better use, though results can differ. The words don't mean that a worn joint will rebuild itself.

Simple notes help the provider understand the ache

Record when soreness began and what you were doing. Add any swelling, warmth, stiffness, weakness, or locking you've noticed.

Take past test results and a list of earlier care. That saves time and shows what still needs an answer.

Ask what the medical provider, the health worker examining you, thinks is causing the soreness. Then ask what the provider saw or felt during the exam that supports that answer.

The visit needs to end with cost, follow-up time, and a clear next step. You shouldn't leave wondering how long to wait before calling back.

Sources

1. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

2. A network meta-analysis of 43 trials (5,554 patients) reached the OPPOSITE ranking to the more recent orthobiologic-favourable reviews: steroids ranked most likely to be effective for pain and function, with adipose MSC and multiple PRP ranked LEAST likely; single PRP, multiple PRP and adipose MSC did not produce a relevant reduction in pain or improvement in function versus placebo. The authors noted treatment-effect differences were small and potentially not clinically meaningful either way.

   Han SB, et al. — Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2020.03.041.

3. A frequentist network meta-analysis with a minimum 6-month follow-up found all intra-articular treatments EXCEPT corticosteroid significantly better than placebo. PRP had the highest probability of efficacy for pain, function and both combined, followed by plasma rich in growth factors (PRGF), then HA, then corticosteroid, then placebo.

   Singh H, et al. — Relative Efficacy of Intra-articular Injections in the Treatment of Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. American Journal of Sports Medicine, 2022. DOI: 10.1177/03635465211029659.

4. A network meta-analysis of 79 RCTs (8,761 patients) covering eleven injectables - autologous conditioned serum, BMAC, botulinum toxin, corticosteroid, HA, MSC, ozone, saline placebo, PRP, PRGF and stromal vascular fraction - found the top-ranked treatment CHANGES WITH TIME POINT: high-molecular-weight HA plus corticosteroid ranked first for WOMAC at 4-6 weeks and 3 months, while PRP ranked first at 6 months. This is the clearest demonstration that 'which injection is best' depends entirely on when you measure.

   Anil U, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials.. The Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

5. A Bayesian network meta-analysis restricted to trials with at least one year of follow-up (37 RCTs, 5,089 patients) ranked combined PRP+HA first for both pain relief and function at one year, ahead of PRP alone, then HA+corticosteroid, then HA alone, then placebo, with corticosteroid alone ranked LAST - below placebo.

   Gupta N, et al. — Long-term effectiveness of intra-articular injectables in patients with knee osteoarthritis: a systematic review and Bayesian network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2025. DOI: 10.1186/s13018-025-05574-w.

6. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

7. A fragility-index analysis of the RCTs underpinning PRP for knee OA (1,993 patients) found the mean number of outcome events needed to reverse an individual trial's statistical significance was only 4.57, and 8.67 for the pooled meta-analytic effects. On meta-analysis PRP did show an advantage over hyaluronic acid (OR 2.19) and higher rates of achieving the MCID for pain versus alternatives (OR 6.19) - but the conclusions rest on a small number of events, which is the technical way of saying the literature is not robust.

   Oeding JF, et al. — Platelet-Rich Plasma Versus Alternative Injections for Osteoarthritis of the Knee: A Systematic Review and Statistical Fragility Index-Based Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465231224463.

8. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

9. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.